Publication Name	World Journal of Stem Cells
Manuscript ID	91095
Country	China

Received	2023-12-21 15:07
Peer-Review Started	2023-12-21 15:07
First Decision by Editorial Office Director	2024-02-03 02:37
Return for Revision	2024-02-03 02:37
Revised	2024-02-17 04:09
Publication Fee Transferred
Second Decision by Editor	2024-03-15 02:35
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2024-03-15 07:02
Articles in Press	2024-03-15 07:02
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-04-22 01:35
Publish the Manuscript Online	2024-04-25 05:24

ISSN	1948-0210 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cell Biology
Manuscript Type	Review
Article Title	Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19
Manuscript Source	Invited Manuscript
All Author List	Xiang-Yi Hou, La-Mu Danzeng, Yi-Lin Wu, Qian-Hui Ma, Zheng Yu, Mei-Ying Li and Li-Sha Li
ORCID	Author(s) ORCID Number Xiang-Yi Hou http://orcid.org/0009-0000-1510-3692 La-Mu Danzeng http://orcid.org/0009-0007-8573-8694 Yi-Lin Wu http://orcid.org/0009-0002-3053-1438 Qian-Hui Ma http://orcid.org/0009-0002-8684-509X Zheng Yu http://orcid.org/0009-0001-4612-7547 Mei-Ying Li http://orcid.org/0000-0003-4802-5859 Li-Sha Li http://orcid.org/0000-0003-4048-5981
Funding Agency and Grant Number	Funding Agency Grant Number Science and Technology Department Project of Jilin Province, China 20230101163JC Outstanding Youth Fund Project of Jilin Provincial Department of Education, China JJKH20241324KJ
Corresponding Author	Li-Sha Li, PhD, Professor, The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, No. 126 Xinmin Street, Changchun 130021, Jilin Province, China. lilisha@jlu.edu.cn
Key Words	COVID-19; Cytokine storm; Immunomodulation; Mesenchymal stem cell; Mesenchymal stem cell-derived exosomes
Core Tip	As the coronavirus disease 2019 (COVID-19) pandemic normalizes, developing efficient treatments is critical to reducing the strain on the healthcare system. We summarize the various current treatments for COVID-19 and the mechanisms of damage caused by severe acute respiratory syndrome coronavirus 2. Through the comparison to existing treatments, we find that stem cell therapy has more research value. Mesenchymal stem cells (MSC) and their derived exosomes (MSC-Exo) have homing, immunomodulatory, and tissue repair abilities. They can reduce lung injury and inhibit pulmonary fibrosis. We summarized the clinical trials in recent years, analyzed the safety and effectiveness of MSC and MSC-Exo treatment from various aspects such as mechanism of action and therapeutic effect, and provided substantial theoretical support for their clinical application.
Publish Date	2024-04-25 05:24
Citation	Hou XY, Danzeng LM, Wu YL, Ma QH, Yu Z, Li MY, Li LS. Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19. World J Stem Cells 2024; 16(4): 353-374
URL	https://www.wjgnet.com/1948-0210/full/v16/i4/353.htm
DOI	https://dx.doi.org/10.4252/wjsc.v16.i4.353

Full Article (PDF)	WJSC-16-353-with-cover.pdf